Analyst Research Report Snapshot

Title:

ALK-ABELLÓ - UNANIMOUS FDA ADCOMM VOTE FOR GRASTEK

Price:

$10.00

Provider:

Edison Investment Research

Date:

19 Dec 2013

Pages:

2

Type:

AcrobatPDF

Companies referenced:

ALKb.CO

Available for Immediate Download
Summary:

The US FDA Allergenic Products Advisory Committee Meeting (APAC) voted unanimously in favour of ALK and partner Merck’s Grastek allergy immunotherapy tablet for the treatment of severe grass pollen allergy. On day two of the meeting, the APAC focused mainly on safety, with similar concerns regarding severe reactions and particular subgroups. Overall, there was general enthusiasm for the product, with some members supporting a disease-modifying claim for the treatment.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.